POLYENDOCRINE METABOLIC OVARIAN SYNDROME: REFRAMING POLYCYSTIC OVARY SYNDROME AS A MULTISYSTEM DISORDER

Abstract

Background: Polycystic Ovary Syndrome (PCOS) is traditionally classified as a localized gynecological disorder. However, accumulating clinical and molecular evidence demonstrates that it is a complex, systemic endocrine-metabolic condition. The current nomenclature—focused entirely on ovarian morphology—creates significant diagnostic bias and clinical fragmentation.

Objective: This manuscript presents a clinical rationale for reframing PCOS as Polyendocrine Metabolic Ovarian Syndrome (PMOS) to better reflect its multi-organ pathogenesis and drive comprehensive, cross-disciplinary management.

Methods: A narrative review of current literature regarding insulin resistance, neuroendocrine disruption, and metabolic sequelae in patients diagnosed with PCOS under the Rotterdam criteria was conducted

Results: The primary drivers of this condition extend far beyond the ovaries, involving hypothalamic-pituitary-adrenal (HPA) axis acceleration, profound peripheral insulin resistance, hepatic metabolic alterations, and chronic low-grade tissue inflammation. Ovarian cysts are a variable, secondary feature of this broader metabolic cascade rather than a mandatory root cause.

Conclusion: Transitioning to the diagnostic framework of PMOS de-emphasizes pure ovarian morphology. This shift is critical to optimizing early cardiovascular, metabolic, and hepatic intervention, ultimately improving long-term patient outcomes.